China grants approval to new therapy for rare blood cancer

The medicine marks the nation’s first homegrown EZH2 inhibitor Jiangsu Hengrui Pharmaceuticals announced on Monday that the National Medical Products Administration has granted conditional authorization for its latest oncology treatment,…

Read more